Advertisement

Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience

  • Julie Blanc
  • Clémence Deschasse
  • Laurent Kodjikian
  • Corinne Dot
  • Alain-Marie Bron
  • Catherine Creuzot-Garcher
Retinal Disorders

Abstract

Purpose

To evaluate the safety and efficacy of repeated dexamethasone intravitreal implants (DEX implants) over 3 years in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Methods

We conducted a 3-year, retrospective, multicenter study that included adult patients with ME secondary to BRVO or CRVO treated with first-line DEX implants. Patients were divided into two different subgroups: patients who received DEX implant injections only (group 1) and those who received DEX implants first and then were switched to anti-VEGF agents (group 2). Primary endpoints were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 6 and month 36. Secondary endpoints included changes in both BCVA and CRT after each DEX implant and adverse events, particularly cataract extraction and elevated intraocular pressure (IOP).

Results

Sixty-six patients with a median [IQR (interquartile ratio)] age of 72 [65.0; 81.1] years were included (40.9% BRVO, 59.1% CRVO), who received a median of 5.0 [min, 1.0; max, 10.0] DEX implants over 3 years. Median [IQR] time to retreatment was 4.8 [4.2; 6.0] months. The median [IQR] improvements in BCVA from baseline until months 6 and 36 were respectively + 10.0 [0; + 20.0] letters (P = 0.040) and + 10.0 [− 8.7; + 20.0] letters (P = 0.364) in the whole population. In group 1, the results were similar, whereas in group 2, BCVA significantly increased at M36 compared with baseline (P = 0.003). The median [IQR] CRT reductions from baseline to months 6 and 36 were respectively − 227.5 [− 337.0; − 52.7] μm and − 224.0 [− 405.0; − 83.8] μm (P < 0.001) in the whole population. Results were similar in both groups. The most common adverse events were cataract extraction (70.4%) and elevated IOP (54.5%). No other serious local complications were observed. Treatment was switched to anti-VEGF agents in 16 (24.2%) patients.

Conclusions

DEX implants are an effective treatment for BRVO and CRVO-associated ME over 3 years. It is a valid treatment even though complications remain frequent. However, functional efficacy seems to decrease with time and repeated injections.

Keywords

Dexamethasone Intravitreal injection Retinal vein occlusion Macular edema 

Notes

Acknowledgements

The authors gratefully thank Apolline Mairot for her collaboration and her assistance in collecting data.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (place name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732.  https://doi.org/10.1001/archopht.124.5.726 CrossRefPubMedGoogle Scholar
  2. 2.
    Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 8:1886–1894.  https://doi.org/10.1111/j.1538-7836.2010.03909.x CrossRefPubMedGoogle Scholar
  3. 3.
    Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319 e311.  https://doi.org/10.1016/j.ophtha.2009.07.017 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, Lackner K, Pfeiffer N, Mirshahi A (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg health study. J Thromb Haemost 13:1254–1263.  https://doi.org/10.1111/jth.12982 CrossRefPubMedGoogle Scholar
  5. 5.
    Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33:901–910.  https://doi.org/10.1097/IAE.0b013e3182870c15 CrossRefPubMedGoogle Scholar
  6. 6.
    Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G (2011) Management of retinal vein occlusion—consensus document. Ophthalmologica 226:4–28.  https://doi.org/10.1159/000327391 CrossRefPubMedGoogle Scholar
  7. 7.
    Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D (2015) Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int 2015:870987.  https://doi.org/10.1155/2015/870987 PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    (1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486–491Google Scholar
  9. 9.
    Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD, Bakri SJ (2017) Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology 124:1412–1423.  https://doi.org/10.1016/j.ophtha.2017.03.060 CrossRefPubMedGoogle Scholar
  10. 10.
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Group OGS (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146 e1133.  https://doi.org/10.1016/j.ophtha.2010.03.032 CrossRefPubMedGoogle Scholar
  11. 11.
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GSG, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460.  https://doi.org/10.1016/j.ophtha.2011.05.014 CrossRefPubMedGoogle Scholar
  12. 12.
    SF0 Intravitreal Injection. French Society of Ophthalmology http://www.sfo.asso.fr/files/files//FICHE-INFO-PATIENT_/Fiche_65_Injection_intravitreenne_18janv16(1).pdf: Accessed 19 Feb2018
  13. 13.
    Korobelnik JF, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S, Velard ME (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254:2307–2318.  https://doi.org/10.1007/s00417-016-3394-y CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fortoul V, Denis P, Kodjikian L (2015) Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study. Eye (Lond) 29:769–775.  https://doi.org/10.1038/eye.2015.36 CrossRefGoogle Scholar
  15. 15.
    Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up—the SOLO study. Acta Ophthalmol 91:e340–e347.  https://doi.org/10.1111/aos.12020 CrossRefPubMedGoogle Scholar
  16. 16.
    Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A (2013) Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 27:65–71.  https://doi.org/10.1038/eye.2012.226 CrossRefGoogle Scholar
  17. 17.
    Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, Group C-CS (2016) Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267.  https://doi.org/10.1016/j.ajo.2016.04.020 CrossRefPubMedGoogle Scholar
  18. 18.
    Pommier S, Meyer F, Guigou S, Barthelemy T, Gobert F, Hajjar C, Merite PY, Parrat E, Rouhette H, Matonti F (2016) Long-term real-life efficacy and safety of repeated Ozurdex(R) injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study. Ophthalmologica 236:186–192.  https://doi.org/10.1159/000452896 CrossRefPubMedGoogle Scholar
  19. 19.
    Danis RP, Sadda S, Jiao J, Li XY, Whitcup SM (2016) Relationship between retinal thickness and visual acuity in eyes with retinal vein occlusion treated with dexamethasone implant. Retina 36:1170–1176.  https://doi.org/10.1097/IAE.0000000000000851 CrossRefPubMedGoogle Scholar
  20. 20.
    Noma H, Funatsu H, Mimura T, Harino S, Shimada K (2011) Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema. Retina 31:2102–2108.  https://doi.org/10.1097/IAE.0b013e318212e24d CrossRefPubMedGoogle Scholar
  21. 21.
    Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34:342–351.  https://doi.org/10.1097/IAE.0b013e318297f842 CrossRefPubMedGoogle Scholar
  22. 22.
    Bakri SJ, Omar AF, Iezzi R, Kapoor KG (2016) Evaluation of multiple dexamethasone Intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 36:552–557.  https://doi.org/10.1097/IAE.0000000000000750 CrossRefPubMedGoogle Scholar
  23. 23.
    Chiquet C, Bron AM, Straub M, Dupuy C, Isaico R, Aptel F, Creuzot-Garcher C (2016) Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Res 55:152–158.  https://doi.org/10.1159/000442258 CrossRefPubMedGoogle Scholar
  24. 24.
    Pielen A, Buhler AD, Heinzelmann SU, Bohringer D, Ness T, Junker B (2017) Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-VEGF to dexamethasone implant and vice versa. J Ophthalmol 2017:5831682.  https://doi.org/10.1155/2017/5831682 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hanhart J, Rozenman Y (2017) Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica 238:110–118.  https://doi.org/10.1159/000473864 CrossRefPubMedGoogle Scholar
  26. 26.
    Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G (2015) Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmic Res 53:207–216.  https://doi.org/10.1159/000381187 CrossRefPubMedGoogle Scholar
  27. 27.
    Vie AL, Kodjikian L, Malcles A, Agard E, Voirin N, El Chehab H, Nguyen AM, Dot C (2017) Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37:173–178.  https://doi.org/10.1097/IAE.0000000000001114 CrossRefPubMedGoogle Scholar
  28. 28.
    Li X, Wang N, Liang X, Xu G, Li XY, Jiao J, Lou J, Hashad Y, China Ozurdex in RVOSG (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59–69.  https://doi.org/10.1007/s00417-017-3831-6 CrossRefPubMedGoogle Scholar
  29. 29.
    James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23:403–420.  https://doi.org/10.1089/jop.2006.0067 CrossRefPubMedGoogle Scholar
  30. 30.
    Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478–483CrossRefPubMedGoogle Scholar
  31. 31.
    Renfro L, Snow JS (1992) Ocular effects of topical and systemic steroids. Dermatol Clin 10:505–512CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity HospitalDijonFrance
  2. 2.La Croix-Rousse HospitalUniversity Hospital of LyonLyonFrance
  3. 3.Department of OphthalmologyDesgenettes Military HospitalLyonFrance
  4. 4.Eye and Nutrition Research Group, CSGA, UMR1324 INRADijonFrance

Personalised recommendations